Genmab Lands Potential $1.1B J&J Cancer Drug Deal

Law360, Washington (August 30, 2012, 2:20 PM EDT) -- Danish drugmaker Genmab A/S has licensed a multiple myeloma treatment to Johnson & Johnson subsidiary Janssen Biotech Inc. in a potential $1.1 billion development and commericalization deal, the companies announced Thursday.

Genmab forked over the rights to daratumumab in exchange for an upfront $55 million payment from Janssen and approximately $80 million stock investment from Johnson & Johnson Development Corp., in addition to $1 billion in development, regulatory and sales milestones that could come into play further down the line.

According to the deal terms, Janssen...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.